Etanercept 

Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis^[1][2][3].

Human

Etanercept (10 mg/kg; s.c.; every 3 days for 3 weeks) significantly decreases the mean arthritis scores and radiological score^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

150000 (Average)

185243-69-0

Liquid

Colorless to light yellow

[Etanercept]

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  [TNFRSF1B (tumor necrosis factor receptor (TNFR)superfamily member 1B, TNFBR, p75, CD120b)]2-IGHG1 Fc (Fragment constant)

• 
  Immobilized TNF-alpha/TNFSF2 Protein, Human (His, HY-P7416) can bind Etanercept. The EC₅₀ for this effect is 9.44 ng/mL.

• [1]. Goffe B, et al. Etanercept: An overview. J Am Acad Dermatol. 2003;49(2 Suppl):S105-S111.  [Content Brief]

  [2]. Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther. 1999;21(1):75-2.  [Content Brief]

  [3]. Haraoui B, et al. Etanercept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag. 2007;3(1):99-105.  [Content Brief]

  [4]. Totoson P, et al. Etanercept improves endothelial function via pleiotropic effects in rat adjuvant-induced arthritis. Rheumatology (Oxford). 2016;55(7):1308-1317.  [Content Brief]